Corcept Therapeutics stock analysis
Corcept Therapeutics (HTD) Stock Price & Analysis
HTD Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 6.68B
- Enterprise Value
- CHF 13.83B
- Total Cash (Recent Filing)
- CHF 370.70M
- Total Debt (Recent Filing)
- CHF 8.99M
- Price to Earnings (P/E)
- 49.7
- Beta
- -0.65
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- 0.92
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings Growth
Strong revenue and net-income growth indicate expanding demand and improving operating scale across Corcept’s commercial portfolio. Sustained top-line momentum provides resources to support commercialization and development, while rising earnings strengthen the company’s capacity to fund future growth internally.
Cash Generation And Balance Sheet
Robust free cash flow and minimal leverage give Corcept substantial financial flexibility over the next several quarters. High cash conversion supports internally funded investment in clinical programs and commercialization, while the conservative capital structure reduces refinancing pressure and improves resilience.
Lifyorli Commercial Adoption
Rapid physician and patient adoption gives Corcept a second meaningful commercial growth engine beyond its endocrinology franchise. Increasing repeat prescribing and broader use across oncology settings can support durable revenue expansion as awareness and treatment penetration continue to build.
Bears Say
Operating Margin Compression
Operating-margin compression indicates that higher operating costs or other impacts are absorbing part of the benefit from revenue growth. If this persists, it could limit earnings scalability and reduce the cash available for pipeline investment, commercialization, and other capital-allocation priorities.
Relacorilant Regulatory Execution Risk
The prior complete response letter demonstrates that relacorilant’s regulatory path has already encountered a material setback. Although the resubmitted NDA is under review, another delay or unfavorable decision could postpone a major growth opportunity and increase reliance on existing products.
Product Revenue Concentration
Corcept remains substantially dependent on its established Korlym franchise for revenue, even as Lifyorli expands. Concentration in a limited number of marketed products makes sustained growth more dependent on continued demand, reimbursement access, and successful execution of newer launches and pipeline programs.
Corcept Therapeutics News
HTD FAQ
What is Corcept Therapeutics’s market cap?
When is Corcept Therapeutics’s upcoming earnings report date?
How were Corcept Therapeutics’s earnings last quarter?
Is Corcept Therapeutics overvalued?
Does Corcept Therapeutics pay dividends?
What is Corcept Therapeutics’s EPS estimate?
How many shares outstanding does Corcept Therapeutics have?
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Corcept Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Corcept Therapeutics Stock Smart Score
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Joseph K. Belanoff
- Employees
- 730
- Website
- www.corcept.com
- Address
- 101 Redwood Shores Parkway, Redwood City, CA, 94065, US
Corcept Therapeutics (HTD) Earnings & Revenues
HTD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with substantial revenue and net-income growth, record endocrinology performance, rapid Lifyorli adoption, positive clinical results and multiple advancing pipeline programs. The company also reiterated its 2026 revenue guidance and highlighted significant future opportunities in Cushing's syndrome, oncology, MASH and ALS. The main negatives were the prior complete response letter for relacorilant, the continuing underdiagnosis of hypercortisolism, the unmet need in platinum-resistant ovarian cancer and limited available information on a potential competing therapy.
View all CH:HTD earnings summaries